Please login to the form below

Not currently logged in
Email:
Password:

Medivir names new CEO

Niklas Prager has experience at Merck & Co and Pfizer
medivir niklas prager

Medivir has named board member Niklas Prager as the company's new CEO replacing Maris Hartmanis.

Prager, who has served on the board of the Swedish biopharma since May 2014, will assume his new position on September 1, 2014.

Birgitta Stymne Göransson, chairman of the board of directors of Medivir, said: “Niklas has a background in both biotech and big pharma, and his large network of contacts in the Swedish and international pharmaceutical industries make him an ideal choice for us.

“Niklas will in particular be able to contribute and strengthen Medivir in the important areas of strategic business development and commercialisation.”

Prager's previous companies include Merck & Co, where he served in both the US and Sweden. His other roles include CEO of Pfizer's business in Sweden.

Commenting on his new position, he highlighted Medivir's work with Johnson & Johnson to develop the hepatitis C treatment Olysio (simeprevir).

“Medivir is an attractive company in an exciting phase of its development following the successful market introduction of simeprevir,” he said.

“An update of Medivir's strategic plan is the number one priority, and work on this is already well under way.”

13th August 2014

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics